Clinical trials: Rituximab, completed
Leukemia
Rituximab to the Preparative Regimen of Etoposide and Total Body Irradiation in Acute Lymphoblastic Leukemia
Primary Objective: To determine the progression free survival (PFS) of the preparative regimen rituximab, etoposide and total body irradiation (TBI), in patients with acute lymphoblastic leukemia (ALL) receiving allogeneic…
- Trial name
- NCT00427791
- Testing
- Etoposide, Total Body Irradiation, Rituximab
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- M.D. Anderson Cancer Center
Primary Central Nervous System Lymphoma
Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System
Primary central nervous system lymphomas are rare aggressive malignancies, usually treated in two steps: an induction phase (where a combination of chemotherapy is given) followed by a consolidation phase (where patients usually…
- Trial name
- FIORELLA (NCT03495960)
- Testing
- Rituximab, Methotrexate, Procarbazine
- Where
- 34 sites in Denmark, Finland and 2 more
- Volunteers
- 72 people
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG)
Indolent B-Cell Non-Hodgkin's Lymphomas
A Study to Evaluate the Efficacy and Safety of Bendamustine Hydrochloride Injection
This is a study to evaluate the efficacy and safety of Bendamustine Hydrochloride Injection in subjects with Rituximab-resistant Indolent B-Cell Non-Hodgkin's Lymphomas.
- Trial name
- NCT04569838
- Testing
- Bendamustine hydrochloride injection
- Where
- 11 sites in China
- Volunteers
- 91 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Rheumatoid Arthritis
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
In this open-label single arm study the safety and efficacy of Mabthera will be evaluated in patients with active rheumatoid arthritis who have had an inadequate response to methotrexate.
- Trial name
- NCT01000610
- Testing
- rituximab [MabThera/Rituxan], methotrexate, methylprednisolone
- Where
- 4 sites in Tunisia
- Volunteers
- 18 people
- Sponsor
- Hoffmann-La Roche
Diffuse Large B-Cell Lymphoma (DLBCL)
A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma
The purpose of this study is to evaluate the preliminary efficacy, safety, and pharmacokinetics of glofitamab (glofit) in combination with rituximab plus ifosfamide, carboplatin, and etoposide (R-ICE) in participants with…
- Trial name
- NCT05364424
- Testing
- Glofitamab, Obinutuzumab, Tocilizumab
- Where
- 9 sites in United States
- Volunteers
- 43 people
- Sponsor
- Hoffmann-La Roche
Chronic Lymphocytic Leukemia
Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia
This is an open-label Phase 2 study to evaluate the safety and efficay of AT-101 in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
- Trial name
- NCT00286780
- Testing
- AT-101
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Ascenta Therapeutics
B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer
Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Conditions
- B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma
- Trial name
- NCT00010192
- Testing
- rituximab, aldesleukin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma
Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial
This phase I trial studies the best dose and side effects of paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel)/rituximab-coated nanoparticle AR160 in treating patients with B-cell non-Hodgkin lymphoma that…
- Conditions
- Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Aggressive Non-Hodgkin Lymphoma
- Trial name
- NCT03003546
- Testing
- Laboratory Biomarker Analysis, Nab-paclitaxel/Rituximab-coated Nanoparticle AR160, Pharmacological Study
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Mayo Clinic
Lymphoma
Peripheral Blood Stem Cell (PBSC) Mobilization in Patients With Relapsed Lymphoma Treated With Bendamustine
Patients with certain types of cancer require treatment with very high doses of chemotherapy. A side effect of high chemotherapy doses is damage to the bone marrow where our blood and immune system cells are produced.
- Trial name
- NCT01022021
- Testing
- Rituximab, Bendamustine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Kansas Medical Center
Diffuse Large B-cell Lymphoma (DLBCL)
Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL)
The purpose of this study is to evaluate the complete response (CR) rate after Intensified 1st cycle Rituximab plus 3rd cycles of R-CHOP in DLBCL
- Trial name
- NCT01054781
- Testing
- Rituximab
- Where
- South Korea
- Volunteers
- 91 people
- Sponsor
- Samsung Medical Center
Rheumatoid Arthritis
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor
This study will evaluate the efficacy and safety of MabThera in patients with active rheumatoid arthritis who have had an inadequate response to one prior anti-TNF alpha inhibitor.
- Trial name
- NCT02079532
- Testing
- rituximab [MabThera]
- Where
- 69 sites in Germany
- Volunteers
- 302 people
- Sponsor
- Hoffmann-La Roche
Purpura, Idiopathic Thrombocytopenic Purpura
Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP)
The purpose of this study is to determine whether Recombinant Human Thrombopoietin (rh-TPO) in combination with Rituximab are effective and safe in the management of Steroid-Resistant/Relapsed Immune Thrombocytopenia (ITP).
- Trial name
- NCT01506414
- Testing
- rhTPO in combination with Rituximab
- Where
- China
- Volunteers
- 91 people
- Sponsor
- Ming Hou
Rheumatoid Arthritis
Demonstrate the Equivalence of CT-P10 to MabThera With Respect to the Pharmacokinetic Profile in Patients With Rheumatoid Arthritis
This randomized,controlled, multicenter, 2-arm, parallel-group, double-blind, prospective, Phase 1 study is designed to demonstrate comparable pharmacokinetics in terms of AUC0-last and Cmax (after second infusion) between CT-P10…
- Trial name
- Triad RA (NCT01534884)
- Testing
- rituximab
- Where
- South Korea
- Volunteers
- 154 people
- Sponsor
- Celltrion
Leukemia, Lymphocytic, Acute
Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage
This goal of this clinical research study is to learn if the combination of methotrexate, pegylated-L-asparaginase, vincristine, and dexamethasone (also rituximab in some patients) can help to control ALL that has not responded…
- Trial name
- NCT00905034
- Testing
- Methotrexate, Vincristine, PEG-l-asparaginase
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Sclerosis
Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate
The purpose of this study is (1) to determine if rituximab induction therapy followed by glatiramer acetate (GA) is substantially superior to placebo rituximab induction followed by GA for the treatment of clinically isolated…
- Trial name
- GATEWAYII (NCT01569451)
- Testing
- Rituximab, Glatiramer Acetate
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- University of Colorado, Denver
Follicular Lymphoma
Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma
The primary objective of the current study is to demonstrate the equivalent efficacy of rituximab (DRL_RI) and MabThera® in subjects with Low Tumor Burden Follicular Lymphoma (LTB-FL).
- Trial name
- FLINTER (NCT03976102)
- Testing
- DRL_RI (Proposed rituximab biosimilar), MabThera®
- Where
- 4 sites in United States
- Volunteers
- 317 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Diffuse, Large B-Cell, Lymphoma
Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.
Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin's lymphoma, accounting for between 30% and 50% of the patients.
- Trial name
- NCT01848132
- Testing
- Bortezomib, Rituximab, Cyclophosphamide
- Where
- 21 sites in Spain
- Volunteers
- 121 people
- Sponsor
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Secondary Immune Deficiency
Humoral Immunodeficiency With Rituximab and Therapy With Subcutaneous Ig
To study the use of subcutaneous (injected under the skin) immunoglobulin replacement therapy (replacement of antibodies, which are infection-fighting proteins) in patients with a type of blood cancer called lymphoma, who have…
- Trial name
- NCT03211065
- Testing
- 20% subcutaneous immunoglobulin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Rochester General Hospital
Follicular Lymphoma, Small Lymphocytic Lymphoma
A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma
Despite strong evidence suggesting that vitamin D deficiency is associated with undesirable outcomes in patients with numerous cancers, there has never been a thorough study of vitamin D treatment in subjects undergoing treatment…
- Conditions
- Follicular Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Mucosal-Associated Lymphoid Tissue Lymphoma
- Trial name
- ILyAD (NCT03078855)
- Testing
- Vitamin D, Rituximab
- Where
- 7 sites in United States
- Volunteers
- 211 people
- Sponsor
- Jonathan Friedberg
Multiple Myeloma and Plasma Cell Neoplasm
Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma
RATIONALE: Giving chemotherapy followed by treated T cells before a stem cell transplant stops the growth of cancer cells by stopping them from dividing or by killing them.
- Trial name
- NCT00938626
- Testing
- anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.